Pharma RSS Digest - 2026-05-09
Overview
The pharma and medtech landscape on May 9, 2026, is shaped by two distinct but significant developments: a major licensing deal addressing Bayer's looming patent vulnerability in ophthalmology, and a serious Class I device recall underscoring ongoing quality concerns in the supply chain. Bayer's acquisition of Perfuse Therapeutics represents a strategic move to future-proof its flagship ophthalmology franchise ahead of Eylea's patent expirations, while the Namic RA syringe recall highlights patient safety risks that could have broad implications for surgical kit manufacturers and healthcare facilities. Neither story involved regulatory approval decisions for new drugs, and the tape remains relatively light given the absence of major clinical trial readouts or policy announcements. Market participants will want to monitor whether Bayer's bet on PER-001 translates into competitive differentiation, and whether the recall triggers broader supply chain scrutiny.
Key Developments
Bayer Acquires Perfuse to Shore Up Ophthalmology Pipeline
Bayer announced an agreement to acquire Perfuse Therapeutics for up to $2.45 billion, gaining the lead candidate PER-001, a small molecule endothelin receptor antagonist currently in Phase II trials for open-angle glaucoma and diabetic retinopathy. The deal structure includes a $300 million upfront payment with up to $2.15 billion in potential milestone payments tied to development, regulatory, and commercial achievements. PER-001 is delivered via an intravitreal bio-erodible implant and has shown positive Phase IIa results, with 37.5% of high-dose glaucoma patients achieving at least 7 dB visual field improvement versus 0% in the control group at six months. The acquisition is subject to Perfuse shareholder approval and antitrust clearances, with Perfuse headquartered in San Francisco and R&D operations in Durham, North Carolina. Bayer's head of business development, Juergen Eckhardt, and Perfuse founder and CEO Sevgi Gurkan were cited as key figures in the transaction.
This deal matters because Bayer's ophthalmology revenue is heavily concentrated in Eylea, which generated $8.04 billion in combined sales last year but faces its first formulation patent expiration on June 14, 2027, with U.S. Q1 2026 sales already down 10% year-over-year at $941 million. PER-001 offers a differentiated mechanism from anti-VEGF therapies like Eylea, potentially giving Bayer a next-generation product to maintain leadership in a therapeutic area where Regeneron co-markets Eylea. The deal also provides Bayer with preclinical assets for dry AMD and geographic atrophy, expanding its pipeline beyond the two Phase II programs. Watch for Perfuse shareholder voting results and any antitrust review timeline updates, as these will determine whether the deal closes and when Bayer can begin integrating PER-001 into its commercial strategy.
Class I Recall Issued for Namic RA Syringes in Convenience Kits
Medical Action Industries issued a Class I recall—the FDA's most serious classification—for convenience kits containing Namic RA syringes after the syringe rotating adaptor was found to potentially unwind during use, which can cause loose connections or full disconnection between the syringe and manifold. The defect poses serious patient safety risks including biohazard exposure, blood loss, infection, and air embolism, all of which may result in serious injury or death. Four serious injuries have been reported as of March 13, though no deaths have been reported. The recall encompasses Halyard Kit - Pack Cath BHH 5/Cs BANNER (Model BHCA49K, UDI: 0809160490294) across eight specific lot numbers. Medline Industries, which issued the recall notice, has directed customers to remove and destroy all affected Namic RA syringes, though if use is unavoidable, extreme caution and 100% continuous monitoring is required. The FDA issued an Early Alert on April 10 and formally classified the recall as Class I on May 7, 2026.
This recall matters because Class I designations signal potential for serious injury or death and create immediate operational burdens for healthcare facilities that must identify, quarantine, and label affected kits. The affected products are convenience kits used in surgical procedures, suggesting broad potential impact across multiple procedure types. With four serious injuries already reported, the recall could prompt scrutiny of supplier quality management systems and potentially accelerate adoption of alternative syringe products. Watch for updates on whether additional injuries have occurred since the March 13 reporting date, any announcements regarding replacement product availability, and whether the FDA initiates broader manufacturing site inspections in response to this defect.
Watchlist
- The eight specific lot numbers affected by the Namic RA syringe recall remain in various stages of distribution and use, meaning additional injury reports could emerge as facilities complete their audits of inventory. [link]
- Whether Perfuse Therapeutics shareholders approve the acquisition deal, and the timeline for antitrust clearance proceedings, will be critical near-term catalysts for Bayer shareholders assessing deal execution risk.
- The dry AMD and geographic atrophy program acquired from Perfuse remains in preclinical stages, representing a high-risk, high-reward opportunity that could expand Bayer's ophthalmology reach but will require years of development investment.